/
ENTA
$14.51+$0.51 (+3.64%)live
Held by
1
portfolio on TandT
Bookmarked by
0
users
Avg position size
0.1%
of holders' portfolios
13F filers
1
institution
Market cap
$407.1M
29M shares
52-week range
$6.44 – $17.15
75% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Price (6 mo)
Loading chart…
Change$-29.50
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $206.6M | $205.2M | $122.5M | $97.1M | $86.2M | $79.2M | $67.6M | $65.3M |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $4.6M |
| Gross profit | $206.6M | $205.2M | $122.5M | $97.1M | $86.2M | $79.2M | $67.6M | $60.7M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 93.0% |
| R&D | $94.9M | $142.2M | $136.8M | $174.1M | $164.5M | $163.5M | $131.5M | $106.7M |
| Operating income | $88.3M | $36.7M | −$41.6M | −$109.6M | −$123.8M | −$137.2M | −$121.7M | −$85.3M |
| EBITDA | $90.8M | $40.0M | −$38.0M | −$104.2M | −$119.2M | −$123.5M | −$104.5M | −$70.8M |
| Net income | $72.0M | $46.4M | −$36.2M | −$79.0M | −$121.8M | −$133.8M | −$116.0M | −$81.9M |
| Net margin | 34.8% | 22.6% | -29.5% | -81.4% | -141.3% | -169.0% | -171.6% | -125.4% |
| EPS (diluted) | 3.48 | 2.21 | -1.81 | -3.92 | -5.91 | -6.38 | -5.48 | -3.84 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $68M | $-2.28 | $-2.77–$-1.77 | 4 |
| 2027 | $67M | $-1.97 | $-2.60–$-1.35 | 4 |
| 2028 | $75M | $-1.91 | $-3.53–$-1.19 | 4 |
| 2029 | $96M | $-1.78 | $-1.91–$-1.59 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Enanta Pharmaceuticals, Inc
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
www.enanta.com- Employees
- 120
- IPO / List date
- Mar 21, 2013
- HQ
- WATERTOWN, MA
Held by traders on TradeandTell
| Trader / Portfolio | Conviction |
|---|---|
| Robinhood — Robinhood Individualb | — |
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 665,258 | $8.4M |
Insider activity (SEC Form 4)
